In this test-specific episode of the "Answers From the Lab" podcast, David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' new MASS-FIX Quantitation assay offers higher specificity for quantitating m-proteins in the blood, which are associated with multiple myeloma and other diseases. The new MASS-FIX Quantitative assay further enhances the MASS-FIX mass spectrometry method developed at Mayo Clinic, of which greatly improved screening for M-proteins.

The new assay (test code: QMPSS) provides greater specificity and the ease of ordering the right test at the right time for patients, for diagnostic or monitoring purposes.

"With Quantitative MASS-FIX, we're now able to achieve a significantly more specific level of quantitation than we had for SPEP," Dr. Murray says. "This new method is going to replace the traditional SPEP and immunofixation, so only one test will need to be ordered."

The new assay, QMPSS, is the fruit of five years of laboratory work, including building unique software to perform the quantitation. "Our new assay brings in more sensitivity and specificity. This is going to change the way patients are treated," Dr. Murray says.

Listen to learn more about Mayo Clinic Laboratories' MASS-FIX Quantitation assay.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

QMPSS   | Monoclonal Protein Study, Quantitative, Serum

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less